Primary progressive multiple sclerosis (MS) has long been recognised as presenting great difficulties to our management of
what is increasingly a treatable neurological disease.
Saskatchewan says multiple sclerosis liberation therapy clinical trial cancelled
The Physiological Changes of MS
Saskatchewan says multiple sclerosis liberation therapy clinical trial cancelled
The Physiological Changes of MS
Durham, NC (PRWEB) September 09, 2013
As stem cell clinical trials for multiple sclerosis (MS) patients
become more common, it is crucial for researchers to understand the
biologic changes and therapeutic effects of older donor stem cells.
For decades, the question of social selection vs social causation has been raised by public health researchers and social
scientists to explain the association between socioeconomic factors and mood disorders.
In 1960, Donald Acheson1 made the seminal observation that the global distribution of multiple sclerosis (MS) may be related to available hours of
sunshine; this observation was met with disbelief at the time.
To
determine whether brain atrophy and lesion volumes predict subsequent
10 year clinical evolution in multiple sclerosis
(MS). This large multicentre study
points to the complementary predictive value of atrophy and lesion
volumes for predicting long
term disability in MS.
Attributions and self-efficacy for physical activity in multiple sclerosis.
Self-efficacy is an important predictor of health-related physical activity in multiple sclerosis (MS). While past experiences are believed to influence efficacy beliefs, the explanations individuals provide for these experiences also may be critical.
Second line use of Fingolimod is as effective as (Tysabri) Natalizumab in a German out-patient RRMS-cohort.
Although Fingolimod is registered as a second-line drug in relapsing-remittend multiple sclerosis (RRMS) in Europe there are no clinical studies available comparing Fingolimod (FTY) and Natalizumab (N).
Which
is the goal of cognitive rehabilitation in multiple sclerosis: the
improvement of cognitive performance or the perception of cognitive
deficits?Multiple Sclerosis Journal. published 9 September 2013,
Comparing long-term results of PASAT and SDMT scores in relation to neuropsychological testing in multiple sclerosis
Multiple Sclerosis Journal. published 9 September 2013,
Protein array-based profiling of CSF identifies RBPJ as an autoantigen in
multiple sclerosis
Neurology. 2013; 81(11): p. 956-963
Hunting for autoantibodies in multiple sclerosis
Neurology. 2013; 81(11): p. 944-945
Neuroborreliosis during natalizumab treatment in multiple sclerosis
Neurology. 2013; 81(11): p. 1012-1014
